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

White Papers and Resources

Please find below the latest White Papers provided by agencies and companies within the healthcare and pharmaceutical industry. These are provided by external comoanies and are not approved of, checked or edited by PMLiVE or PMGroup Worldwide Ltd.

Webcast: The virtual patient: How to use AI-powered conjoint to understand complex treatment decisions

January 13, 2023 | White Papers and Resources |

Watch to find out how a combination of virtual patients and artificial intelligence can help you to better understand physicians’ decision making processes.

Brought to you by Inizio

Virtual Tools for Promoting Diversity in Pharma and Clinical Trials

January 9, 2023 | White Papers and Resources |

It is no secret that Pharma (still) has a major diversity problem.

Brought to you by Impetus Digital

You’re sitting on a time bomb, so think harder and give more!

January 6, 2023 | White Papers and Resources |

A new philosophy for a new age?

Brought to you by Page & Page Health

Can Artificial Intelligence Solve the Healthcare Crisis?

December 13, 2022 | White Papers and Resources |

Healthcare systems around the world are already struggling to meet the demands of an ageing population, the rising incidence of chronic diseases, escalating healthcare costs …

Brought to you by Page & Page Health

Infographic: Therapy Watch Hyperlipidaemia

December 7, 2022 | White Papers and Resources |

Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study.

Brought to you by Inizio

Article: The rise of the healthcare influencer

December 7, 2022 | White Papers and Resources |

In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space.

Brought to you by Inizio

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings

December 5, 2022 | White Papers and Resources |

After more than two years of pandemic restrictions, many Pharma leaders are itching to meet with their key opinion leaders (KOLs) face-to-face again, believing that’s …

Brought to you by Impetus Digital